Truist on AdaptHealth (AHCO): 'Nice Strategic Move As Diabetes Divestiture Announced'
Tweet Send to a Friend
Truist Securities analyst David MacDonald reiterated a Buy rating and $14.00 price target on AdaptHealth (NASDAQ: AHCO).The analyst commented: "Nice ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
